Miguel N. Rivera, MD, MGH Research Scholar Profile
Miguel Rivera, MD, is investigating how abnormalities in gene regulation in pediatric brain and bone cancers (medulloblastoma and Ewing sarcoma respectively) drive the growth of these tumors.
Dr. Rivera is a board certified pathologist who directs a research laboratory at the MGH Department of Pathology and the MGH Cancer Center. He also serves as attending physician in the clinical molecular diagnostics laboratory at MGH. Dr. Rivera received an A.B. in Molecular Biology from Princeton University in 1996 and an M.D. from Harvard Medical School in 2001. He completed his Anatomic Pathology residency at Brigham and Wome?s Hospital and a fellowship in Molecular Diagnostics at the Harvard Combined Program. During his postdoctoral fellowship, Dr. Rivera identified the tumor suppressor gene WTX which is implicated in both tumor formation and stem cell biology. His research currently focuses on the connections between cancer and normal developmental processes and on the use of genomic technologies to identify pathways that are active in tumors and that may serve as therapeutic targets.
Clinical Interests:
Treats:
Languages:
Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Our laboratory uses genomic technologies to identify and characterize pathways implicated in pediatric solid tumors and sarcomas. Read more about the Rivera Lab.
Selected Publications:
Rivera MN, Kim WJ, Wells J, Stone A, Burger A, Coffman EJ, Zhang J, Haber DA (2009). The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proceedings of the National Academy of Sciences U S A, 106(20):8338-43.
Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA (2007). An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science, 315: 642-5.
Rivera MN, Haber DA (2005) Wilms tumor: connecting tumorigenesis and organ development in the kidney. Nature Reviews Cancer, 5(9):699-712.
Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C (2004). Detection of large-scale variation in the human genome. Nature Genetics, 36(9):949-51.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
Miguel Rivera, MD, is investigating how abnormalities in gene regulation in pediatric brain and bone cancers (medulloblastoma and Ewing sarcoma respectively) drive the growth of these tumors.
The 2019 Scientific Advisory Committee (SAC) meeting reflected a shift in focus from the progress of research at the MGH to the challenges facing members of the hospital’s research faculty.
The 70th meeting of the MGH Scientific Advisory Committee focused on the MGH Research Institute, which was founded in 2015 as an organizational home for the more than 8,500 MGHers in 30 departments, centers and institutes who make up the largest hospital-based research program in the U.S.
How the EWS-FLI1 fusion protein promotes tumor formation in Ewing Sarcoma is not fully understood and is the focus of new research from the lab of Miguel N. Rivera, MD.
Miguel Rivera, MD, is investigating how abnormalities in gene regulation in pediatric brain and bone cancers (medulloblastoma and Ewing sarcoma respectively) drive the growth of these tumors.
The 2019 Scientific Advisory Committee (SAC) meeting reflected a shift in focus from the progress of research at the MGH to the challenges facing members of the hospital’s research faculty.
The 70th meeting of the MGH Scientific Advisory Committee focused on the MGH Research Institute, which was founded in 2015 as an organizational home for the more than 8,500 MGHers in 30 departments, centers and institutes who make up the largest hospital-based research program in the U.S.
How the EWS-FLI1 fusion protein promotes tumor formation in Ewing Sarcoma is not fully understood and is the focus of new research from the lab of Miguel N. Rivera, MD.